Dyne Therapeutics, Inc.

DYN

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001818794

SEC filings (opens in a new tab)

In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Dyne Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023 All holders in Q3 2023

13F holders of DYN: Q3 2023 compared with Q4 2023
Measure	Q3 2023	Of which not filed for Q4 2023	Q4 2023	Change
Holders	114	1	124	+11
Shares	59.9M	137.8K	69.9M	+10.2M (+17.0%)
Value	$536.6M	$1.23M	$930.0M	+$394.6M (+73.7%)

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (25)

Institutions that held Dyne Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to DYN in Q4 2023
Institution	Shares	Value	% of portfolio
FCPM III Services B.V.	6,131,079	$81.5M	24.03%
Frazier Life Sciences Management, L.P.	1,184,840	$15.8M	0.84%
Commodore Capital LP	900,000	$12.0M	1.05%
Laurion Capital Management LP	400,000	$5.32M	0.19%
Millennium Management LLC	388,090	$5.16M	0.00%
Federated Hermes, Inc.	375,000	$4.99M	0.01%
Ikarian Capital, LLC	285,900	$3.80M	1.04%
Schonfeld Strategic Advisors LLC	275,699	$3.67M	0.03%
Jennison Associates LLC	202,871	$2.70M	0.00%
Caption Management, LLC	187,288	$2.49M	0.27%
Schroder Investment Management Group	137,751	$1.83M	0.00%
Boothbay Fund Management, LLC	57,200	$760.8K	0.03%
Qube Research & Technologies Ltd	53,344	$709.5K	0.00%
Natixis	40,000	$532.0K	0.00%
XTX Topco Ltd	24,511	$326.0K	0.07%
Trexquant Investment LP	22,822	$303.5K	0.01%
Campbell & CO Investment Adviser LLC	18,500	$246.1K	0.02%
Entropy Technologies, LP	14,794	$196.8K	0.04%
SG Americas Securities, LLC	12,938	$172.0K	0.00%
ProShare Advisors LLC	11,279	$150.0K	0.00%
Quest Partners LLC	1,382	$18.4K	0.00%
Aspect Partners, LLC	725	$9.64K	0.01%
GAMMA Investing LLC	162	$3.47K	0.00%
Quadrant Capital Group LLC	231	$3.07K	0.00%
SRS Capital Advisors, Inc.	230	$3.06K	0.00%

Sold out (14)

Institutions that held Dyne Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of DYN in Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
Altium Capital Management LP	315,000	$2.82M
Walleye Capital LLC	280,276	$2.51M
ExodusPoint Capital Management, LP	184,010	$1.65M
Two Sigma Investments, LP	24,400	$218.6K
Walleye Trading LLC	24,326	$218.0K
TD Asset Management Inc	23,000	$206.1K
Marshall Wace, LLP	22,052	$197.6K
Cornercap Investment Counsel Inc	20,938	$187.6K
Corton Capital Inc.	19,926	$178.5K
Balyasny Asset Management LLC	17,646	$158.1K
AQR Capital Management LLC	11,644	$104.3K
Spire Wealth Management	400	$3.58K
EverSource Wealth Advisors, LLC	90	$806
Nisa Investment Advisors, LLC	35	$314

Not filed for Q4 2023 yet (1)

Institutions that held Dyne Therapeutics, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding DYN in Q3 2023 that haven't filed for Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
International Biotechnology Trust PLC	137,751	$1.23M